Enalapril: the “blood vessel guardian” among antihypertensive drugs

Enalapril is an angiotensin-converting enzyme inhibitor (ACEI) widely used in the treatment of hypertension and heart failure. It exerts antihypertensive effects by inhibiting vasoconstriction and reducing water and sodium retention. This article will focus on its pharmacological mechanism, indications, medication precautions and common products on the market, focusing on analyzing its core efficacy and clinical value, supplemented by manufacturer information and data comparison, to help readers fully understand this classic drug.

Pharmacological mechanism and core functions

Enalapril blocks the conversion of angiotensin I to angiotensin II, directly dilating peripheral blood vessels and reducing aldosterone secretion to achieve "dual-pathway blood pressure reduction." Clinical studies have shown that its blood pressure-lowering effect is stable, and it is especially suitable for patients with hypertension combined with diabetes and kidney disease. The "China Guidelines for the Prevention and Treatment of Hypertension" lists it as a first-line antihypertensive drug, and the World Health Organization (WHO) also recommends it for the long-term management of heart failure.

Indications and medication details

In addition to essential hypertension, enalapril has clear effects on chronic cardiac insufficiency, left ventricular hypertrophy and other diseases. Please note when taking medication: The initial dose is recommended to be 5-10 mg/day, and avoid using it in combination with potassium-sparing diuretics; common side effects include dry cough (incidence rate is about 10%), elevated blood potassium, and patients with renal insufficiency need to adjust the dose. The American Heart Association (AHA) points out that continuous use for 4 weeks can achieve the best blood pressure lowering effect.

Market product and data comparison

Scientific medication and long-term value

The advantage of enalapril lies in its target organ protective effect, which can delay the progression of diabetic nephropathy. Professor Ma Changsheng, a cardiovascular expert at Beijing Anzhen Hospital, emphasized: "Regulatory use of ACEI drugs can reduce the risk of cardiovascular and cerebrovascular events by more than 20%." Patients need to regularly monitor kidney function and blood potassium, and follow a low-salt diet. With the development of sustained-release dosage forms, the convenience of medication is gradually improving.

Quote sources:
1. "China Guidelines for the Prevention and Treatment of Hypertension (2023 Revised Edition)"
2. World Health Organization Essential Medicines List (2021)
3. Ma Changsheng "Application of ACEI in Cardiovascular Disease" (Chinese Journal of Cardiovascular Disease)
4. State Food and Drug Administration drug database (as of June 2024)